Effects of Antihypertensive Treatment on Cardiac Remodelling and Metabolic Profile in HIV Infected Patients: Randomized Longitudinal Study With Candesartan Versus Lercanidipine
试验速览
- 阶段
- 4 期
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- metabolic profile
研究概览
简要总结
Human immunodeficiency virus infection and highly active antiretroviral therapy (HAART) are associated with an increased risk of cardiovascular disease: a wide range of alterations in lipid and glucose metabolism has been increasingly recognized in HIV patients treated with HAART. Few data are available on the effects of antihypertensive treatment on cardiac morpho-functional characteristics and metabolic parameters in HIV patients. Aim of the study is to assess the effects of chronic therapy with angiotensin receptor blocker(candesartan)or calcium channel blocker (lercanidipine)on metabolic profile and cardiac remodelling in HIV hypertensive patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •HIV infection
- •office blood pressure > 140/90 mmHg
- •no antihypertensive treatment
- •good quality echocardiogram
排除标准
- •cardiovascular diseases
- •hypothyroidism
- •secondary hypertension
- •hepatic and renal failure
研究组 & 干预措施
1
candesartan 8-16 mg once daily
干预措施: candesartan (Drug)
2
lercanidipine 10-20 mg once daily
干预措施: lercanidipine (Drug)
结局指标
主要结局
metabolic profile
时间窗: one year
morpho-functional left ventricle characteristics
时间窗: one year
次要结局
- systolic and diastolic blood pressure(one year)